← Leaderboards
Paresh Dandona
State University Of New York At Buffalo
$5,118,360
Attributed
$5,118,360
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $856.9K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$5,118,360 · 3
By mechanism
R01$5,118,360 · 3
Top collaborators
No co-investigators on record.
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Elizabeth Genevieve Mietlicki-Baase$2,278,450
Others in their field
Top investigators on “Randomized”
- James Dennis Neaton · Northwestern University$305,243,252
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$292,521,996
- Lawrence Corey · Fred Hutchinson Cancer Center$292,521,996
- Marian Ewell · The Emmes Company, Llc$278,931,253
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$199,647,509
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
Research focus
RandomizedSubcutaneousNon-Insulin-Dependent Diabetes MellitusDoseAftercareInsulinBlood Glucose RegulationPlacebosAffectFallsProspectiveInfusion ProceduresAtherosclerosisInsulin SensitivityInflammatoryInhibitor/AntagonistInterleukin-6GenesFatty Acid Glycerol EstersCellsGelatinase BGenerationsAdipose TissueGlucose Clamp
Grant awards (14)
LIRAGLUTIDE AS ADDITIONAL TREATMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS$274,263
R01 · FY2016 · DK · contact PI
LIRAGLUTIDE AS ADDITIONAL TREATMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS$273,754
R01 · FY2015 · DK · contact PI
LIRAGLUTIDE AS ADDITIONAL TREATMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS$273,754
R01 · FY2014 · DK · contact PI
LIRAGLUTIDE AS ADDITIONAL TREATMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS$264,173
R01 · FY2013 · DK · contact PI
Testosterone effects on insulin sensitivity & inflammation in T2DM and obesity$552,103
R01 · FY2012 · DK · contact PI
LIRAGLUTIDE AS ADDITIONAL TREATMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS$274,772
R01 · FY2012 · DK · contact PI
Testosterone effects on insulin sensitivity & inflammation in T2DM and obesity$545,114
R01 · FY2011 · DK · contact PI
HYPOGONADOTROPIC HYPOGONADISM, INSULIN SENSITIVITY AND INFLAMMATION IN TYPE 2 DIA$600,545
R01 · FY2010 · DK · contact PI
HYPOGONADOTROPIC HYPOGONADISM, INSULIN SENSITIVITY AND INFLAMMATION IN TYPE 2 DIA$553,100
R01 · FY2009 · DK · contact PI
Inflammation in obesity: Modulation by Weight Loss$303,808
R01 · FY2009 · DK · contact PI
Inflammation in obesity: Modulation by Weight Loss$308,633
R01 · FY2008 · DK · contact PI
Inflammation in obesity: Modulation by Weight Loss$305,759
R01 · FY2007 · DK · contact PI
Inflammation in obesity: Modulation by Weight Loss$305,747
R01 · FY2006 · DK · contact PI
Inflammation in obesity: Modulation by Weight Loss$282,835
R01 · FY2005 · DK